首页 | 本学科首页   官方微博 | 高级检索  
     


Reversing LRP5‐Dependent Osteoporosis and SOST Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity
Authors:Hansjoerg Keller  Jonathan H Gooi  Corinne Collett  David Jenkins  Seth A Ettenberg  Feng Cong  Christine Halleux  Michaela Kneissel
Affiliation:1. Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland;2. Institut National de la Santé et de la Recherche Médicale (National Institute of Health and Medical Research) U942, Assistance Publique–H?pitaux de Paris (AP‐HP), H?pital Lariboisière, Service de Biochimie, Paris, France;3. Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA;4. Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
Abstract:The bone formation inhibitor sclerostin encoded by SOST binds in vitro to low‐density lipoprotein receptor‐related protein (LRP) 5/6 Wnt co‐receptors, thereby inhibiting Wnt/β‐catenin signaling, a central pathway of skeletal homeostasis. Lrp5/LRP5 deficiency results in osteoporosis‐pseudoglioma (OPPG), whereas Sost/SOST deficiency induces lifelong bone gain in mice and humans. Here, we analyzed the bone phenotype of mice lacking Sost (Sost?/?), Lrp5 (Lrp5?/?), or both (Sost?/?;Lrp5?/?) to elucidate the mechanism of action of Sost in vivo. Sost deficiency–induced bone gain was significantly blunted in Sost?/?;Lrp5?/? mice. Yet the Lrp5 OPPG phenotype was fully rescued in Sost?/?;Lrp5?/? mice and most bone parameters were elevated relative to wild‐type. To test whether the remaining bone increases in Sost?/?;Lrp5?/? animals depend on Lrp6, we treated wild‐type, Sost?/?, and Sost?/?;Lrp5?/? mice with distinct Lrp6 function blocking antibodies. Selective blockage of Wnt1 class–mediated Lrp6 signaling reduced cancellous bone mass and density in wild‐type mice. Surprisingly, it reversed the abnormal bone gain in Sost?/? and Sost?/?;Lrp5?/? mice to wild‐type levels irrespective of enhancement or blockage of Wnt3a class‐mediated Lrp6 activity. Thus, whereas Sost deficiency–induced bone anabolism partially requires Lrp5, it fully depends on Wnt1 class–induced Lrp6 activity. These findings indicate: first, that OPPG syndrome patients suffering from LRP5 loss‐of‐function should benefit from principles antagonizing SOST/sclerostin action; and second, that therapeutic WNT signaling inhibitors may stop the debilitating bone overgrowth in sclerosing disorders related to SOST deficiency, such as sclerosteosis, van Buchem disease, and autosomal dominant craniodiaphyseal dysplasia, which are rare disorders without viable treatment options. © 2014 American Society for Bone and Mineral Research.
Keywords:SOST/SCLEROSTIN  WNT/LRP5/6  OSTEOPOROSIS‐PSEUDOGLIOMA  OPPG  SCLEROSING BONE DISORDERS  GENETIC ANIMAL MODELS
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号